# Resmed Inc: financial statements, quarterly

RMD · NYSE · CIK 943819 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/rmd.md) · [Financials](/companies/rmd/financials.md) · [Filings](/companies/rmd/filings.md) · [Insiders](/companies/rmd/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rmd/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,102](/filings/0000943819-24-000027.md) | [1,163](/filings/0000943819-25-000004.md) | [1,197](/filings/0000943819-25-000008.md) | [1,223 d](/filings/0000943819-26-000047.md) | [1,225](/filings/0000943819-25-000090.md) | [1,282](/filings/0000943819-26-000007.md) | [1,292](/filings/0000943819-26-000025.md) | [1,348 d](/filings/0000943819-26-000047.md) | [1,336](/filings/0000943819-25-000090.md) | [1,423](/filings/0000943819-26-000007.md) | [1,431](/filings/0000943819-26-000025.md) | [1,464 d](/filings/0000943819-26-000047.md) |
| Cost of revenue | $m | [502](/filings/0000943819-24-000027.md) | [516](/filings/0000943819-25-000004.md) | [504](/filings/0000943819-25-000008.md) | [508 d](/filings/0000943819-26-000047.md) | [507](/filings/0000943819-25-000090.md) | [531](/filings/0000943819-26-000007.md) | [525](/filings/0000943819-26-000025.md) | [528 d](/filings/0000943819-26-000047.md) | [515](/filings/0000943819-25-000090.md) | [544](/filings/0000943819-26-000007.md) | [540](/filings/0000943819-26-000025.md) | [602 d](/filings/0000943819-26-000047.md) |
| Gross profit | $m | [600](/filings/0000943819-24-000027.md) | [647](/filings/0000943819-25-000004.md) | [693](/filings/0000943819-25-000008.md) | [716 d](/filings/0000943819-26-000047.md) | [717](/filings/0000943819-25-000090.md) | [751](/filings/0000943819-26-000007.md) | [766](/filings/0000943819-26-000025.md) | [820 d](/filings/0000943819-26-000047.md) | [821](/filings/0000943819-25-000090.md) | [879](/filings/0000943819-26-000007.md) | [891](/filings/0000943819-26-000025.md) | [861 d](/filings/0000943819-26-000047.md) |
| Research and development | $m | [75.7](/filings/0000943819-24-000027.md) | [73.9](/filings/0000943819-25-000004.md) | [77.1](/filings/0000943819-25-000008.md) | [80.9 d](/filings/0000943819-26-000047.md) | [79.5](/filings/0000943819-25-000090.md) | [81.4](/filings/0000943819-26-000007.md) | [83.9](/filings/0000943819-26-000025.md) | [86.4 d](/filings/0000943819-26-000047.md) | [87.3](/filings/0000943819-25-000090.md) | [91.0](/filings/0000943819-26-000007.md) | [94.3](/filings/0000943819-26-000025.md) | [106 d](/filings/0000943819-26-000047.md) |
| Selling, general and administrative | $m | [223](/filings/0000943819-24-000027.md) | [222](/filings/0000943819-25-000004.md) | [230](/filings/0000943819-25-000008.md) | [242 d](/filings/0000943819-26-000047.md) | [239](/filings/0000943819-25-000090.md) | [242](/filings/0000943819-26-000007.md) | [245](/filings/0000943819-26-000025.md) | [267 d](/filings/0000943819-26-000047.md) | [259](/filings/0000943819-25-000090.md) | [278](/filings/0000943819-26-000007.md) | [286](/filings/0000943819-26-000025.md) | [296 d](/filings/0000943819-26-000047.md) |
| Operating income | $m | [289](/filings/0000943819-24-000027.md) | [275](/filings/0000943819-25-000004.md) | [375](/filings/0000943819-25-000008.md) | [381 d](/filings/0000943819-26-000047.md) | [387](/filings/0000943819-25-000090.md) | [417](/filings/0000943819-26-000007.md) | [426](/filings/0000943819-26-000025.md) | [455 d](/filings/0000943819-26-000047.md) | [447](/filings/0000943819-25-000090.md) | [492](/filings/0000943819-26-000007.md) | [500](/filings/0000943819-26-000025.md) | [449 d](/filings/0000943819-26-000047.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [52.8](/filings/0000943819-24-000027.md) | [50.7](/filings/0000943819-25-000004.md) | [74.9](/filings/0000943819-25-000008.md) | [65.5 d](/filings/0000943819-26-000047.md) | [72.1](/filings/0000943819-25-000090.md) | [73.7](/filings/0000943819-26-000007.md) | [52.7](/filings/0000943819-26-000025.md) | [78.3 d](/filings/0000943819-26-000047.md) | [98.3](/filings/0000943819-25-000090.md) | [104](/filings/0000943819-26-000007.md) | [104](/filings/0000943819-26-000025.md) | [90.7 d](/filings/0000943819-26-000047.md) |
| Net income | $m | [219](/filings/0000943819-25-000008.md) | [209](/filings/0000943819-25-000008.md) | [300](/filings/0000943819-25-000008.md) | [292 d](/filings/0000943819-26-000047.md) | [311](/filings/0000943819-26-000025.md) | [345](/filings/0000943819-26-000025.md) | [365](/filings/0000943819-26-000025.md) | [380 d](/filings/0000943819-26-000047.md) | [349](/filings/0000943819-26-000025.md) | [393](/filings/0000943819-26-000025.md) | [399](/filings/0000943819-26-000025.md) | [383 d](/filings/0000943819-26-000047.md) |
| Diluted EPS | $ per share | [1.49](/filings/0000943819-24-000027.md) | [1.42](/filings/0000943819-25-000004.md) | [2.04](/filings/0000943819-25-000008.md) | not reported | [2.11](/filings/0000943819-25-000090.md) | [2.34](/filings/0000943819-26-000007.md) | [2.48](/filings/0000943819-26-000025.md) | not reported | [2.37](/filings/0000943819-25-000090.md) | [2.68](/filings/0000943819-26-000007.md) | [2.74](/filings/0000943819-26-000025.md) | not reported |
| Basic EPS | $ per share | [1.49](/filings/0000943819-24-000027.md) | [1.42](/filings/0000943819-25-000004.md) | [2.04](/filings/0000943819-25-000008.md) | not reported | [2.12](/filings/0000943819-25-000090.md) | [2.35](/filings/0000943819-26-000007.md) | [2.49](/filings/0000943819-26-000025.md) | not reported | [2.38](/filings/0000943819-25-000090.md) | [2.69](/filings/0000943819-26-000007.md) | [2.74](/filings/0000943819-26-000025.md) | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [209](/filings/0000943819-23-000029.md) | [210](/filings/0000943819-24-000003.md) | [238](/filings/0000943819-24-000008.md) | [238](/filings/0000943819-25-000035.md) | [426](/filings/0000943819-24-000027.md) | [522](/filings/0000943819-25-000004.md) | [933](/filings/0000943819-25-000008.md) | [1,209](/filings/0000943819-26-000047.md) | [1,384](/filings/0000943819-25-000090.md) | [1,417](/filings/0000943819-26-000007.md) | [1,661](/filings/0000943819-26-000025.md) | [1,469](/filings/0000943819-26-000047.md) |
| Current assets | $m | [2,305](/filings/0000943819-23-000029.md) | [2,378](/filings/0000943819-24-000003.md) | [2,351](/filings/0000943819-24-000008.md) | [2,358](/filings/0000943819-25-000035.md) | [2,641](/filings/0000943819-24-000027.md) | [2,836](/filings/0000943819-25-000004.md) | [3,208](/filings/0000943819-25-000008.md) | [3,506](/filings/0000943819-26-000047.md) | [3,626](/filings/0000943819-25-000090.md) | [3,819](/filings/0000943819-26-000007.md) | [4,064](/filings/0000943819-26-000025.md) | [4,325](/filings/0000943819-26-000047.md) |
| Total assets | $m | [6,741](/filings/0000943819-23-000029.md) | [6,905](/filings/0000943819-24-000003.md) | [6,815](/filings/0000943819-24-000008.md) | [6,872](/filings/0000943819-25-000035.md) | [7,222](/filings/0000943819-24-000027.md) | [7,141](/filings/0000943819-25-000004.md) | [7,567](/filings/0000943819-25-000008.md) | [8,174](/filings/0000943819-26-000047.md) | [8,308](/filings/0000943819-25-000090.md) | [8,503](/filings/0000943819-26-000007.md) | [8,784](/filings/0000943819-26-000025.md) | [8,966](/filings/0000943819-26-000047.md) |
| Current liabilities | $m | [771](/filings/0000943819-23-000029.md) | [764](/filings/0000943819-24-000003.md) | [773](/filings/0000943819-24-000008.md) | [911](/filings/0000943819-25-000035.md) | [904](/filings/0000943819-24-000027.md) | [852](/filings/0000943819-25-000004.md) | [941](/filings/0000943819-25-000008.md) | [1,019](/filings/0000943819-26-000047.md) | [1,256](/filings/0000943819-25-000090.md) | [1,248](/filings/0000943819-26-000007.md) | [1,351](/filings/0000943819-26-000025.md) | [1,395](/filings/0000943819-26-000047.md) |
| Total liabilities | $m | [2,490](/filings/0000943819-23-000029.md) | [2,423](/filings/0000943819-24-000003.md) | [2,185](/filings/0000943819-24-000008.md) | [2,008](/filings/0000943819-25-000035.md) | [2,027](/filings/0000943819-24-000027.md) | [1,888](/filings/0000943819-25-000004.md) | [2,021](/filings/0000943819-25-000008.md) | [2,207](/filings/0000943819-26-000047.md) | [2,187](/filings/0000943819-25-000090.md) | [2,182](/filings/0000943819-26-000007.md) | [2,292](/filings/0000943819-26-000025.md) | [2,381](/filings/0000943819-26-000047.md) |
| Long-term debt | $m | [1,352](/filings/0000943819-23-000029.md) | [1,217](/filings/0000943819-24-000003.md) | [997](/filings/0000943819-24-000008.md) | [697](/filings/0000943819-25-000035.md) | [668](/filings/0000943819-24-000027.md) | [663](/filings/0000943819-25-000004.md) | [663](/filings/0000943819-25-000008.md) | [658](/filings/0000943819-26-000047.md) | [409](/filings/0000943819-25-000090.md) | [404](/filings/0000943819-26-000007.md) | [404](/filings/0000943819-26-000025.md) | [399](/filings/0000943819-26-000047.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | [9.9](/filings/0000943819-23-000029.md) | [9.9](/filings/0000943819-24-000003.md) | [9.9](/filings/0000943819-24-000008.md) | [9.9](/filings/0000943819-25-000035.md) | [9.9](/filings/0000943819-24-000027.md) | [9.9](/filings/0000943819-25-000004.md) | [9.9](/filings/0000943819-25-000008.md) | [9.9](/filings/0000943819-26-000047.md) | [260](/filings/0000943819-25-000090.md) | [260](/filings/0000943819-26-000007.md) | [260](/filings/0000943819-26-000025.md) | [260](/filings/0000943819-26-000047.md) |
| Shareholders' equity | $m | [4,250](/filings/0000943819-25-000008.md) | [4,482](/filings/0000943819-25-000008.md) | [4,630](/filings/0000943819-25-000008.md) | [4,864](/filings/0000943819-26-000047.md) | [5,195](/filings/0000943819-26-000025.md) | [5,253](/filings/0000943819-26-000025.md) | [5,546](/filings/0000943819-26-000025.md) | [5,968](/filings/0000943819-26-000047.md) | [6,121](/filings/0000943819-26-000025.md) | [6,321](/filings/0000943819-26-000025.md) | [6,492](/filings/0000943819-26-000025.md) | [6,585](/filings/0000943819-26-000047.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: not reported
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [286](/filings/0000943819-24-000027.md) | [273 d](/filings/0000943819-25-000004.md) | [402 d](/filings/0000943819-25-000008.md) | [440 d](/filings/0000943819-26-000047.md) | [326](/filings/0000943819-25-000090.md) | [309 d](/filings/0000943819-26-000007.md) | [579 d](/filings/0000943819-26-000025.md) | [539 d](/filings/0000943819-26-000047.md) | [457](/filings/0000943819-25-000090.md) | [340 d](/filings/0000943819-26-000007.md) | [554 d](/filings/0000943819-26-000025.md) | [455 d](/filings/0000943819-26-000047.md) |
| Capital expenditure | $m | [30.0](/filings/0000943819-24-000027.md) | [23.4 d](/filings/0000943819-25-000004.md) | [21.2 d](/filings/0000943819-25-000008.md) | [24.9 d](/filings/0000943819-26-000047.md) | [17.8](/filings/0000943819-25-000090.md) | [20.6 d](/filings/0000943819-26-000007.md) | [20.8 d](/filings/0000943819-26-000025.md) | [30.6 d](/filings/0000943819-26-000047.md) | [43.0](/filings/0000943819-25-000090.md) | [28.5 d](/filings/0000943819-26-000007.md) | [33.7 d](/filings/0000943819-26-000025.md) | [51.1 d](/filings/0000943819-26-000047.md) |
| Dividends paid | $m | [70.6](/filings/0000943819-24-000027.md) | [70.7 d](/filings/0000943819-25-000004.md) | [70.5 d](/filings/0000943819-25-000008.md) | [70.6 d](/filings/0000943819-26-000047.md) | [77.9](/filings/0000943819-25-000090.md) | [77.7 d](/filings/0000943819-26-000007.md) | [77.7 d](/filings/0000943819-26-000025.md) | [77.6 d](/filings/0000943819-26-000047.md) | [87.8](/filings/0000943819-25-000090.md) | [87.6 d](/filings/0000943819-26-000007.md) | [87.2 d](/filings/0000943819-26-000025.md) | [87.1 d](/filings/0000943819-26-000047.md) |
| Share repurchases | $m | [0.0](/filings/0000943819-24-000027.md) | [50.0 d](/filings/0000943819-25-000004.md) | [50.0 d](/filings/0000943819-25-000008.md) | [50.0 d](/filings/0000943819-26-000047.md) | [50.0](/filings/0000943819-25-000090.md) | [75.0 d](/filings/0000943819-26-000007.md) | [75.0 d](/filings/0000943819-26-000025.md) | [100 d](/filings/0000943819-26-000047.md) | [150](/filings/0000943819-25-000090.md) | [175 d](/filings/0000943819-26-000007.md) | [175 d](/filings/0000943819-26-000025.md) | [200 d](/filings/0000943819-26-000047.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2022-09-30) | Q2 FY2023 (2022-12-31) | Q3 FY2023 (2023-03-31) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [147](/filings/0000943819-23-000029.md) | [147](/filings/0000943819-24-000003.md) | [147](/filings/0000943819-24-000008.md) | [147](/filings/0000943819-24-000027.md) | [148](/filings/0000943819-25-000004.md) | [147](/filings/0000943819-25-000008.md) | [148](/filings/0000943819-25-000090.md) | [147](/filings/0000943819-26-000007.md) | [147](/filings/0000943819-26-000025.md) | [147](/filings/0000943819-25-000090.md) | [146](/filings/0000943819-26-000007.md) | [146](/filings/0000943819-26-000025.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 144,252,306 at 2026-08-10, from the cover of the [10-K filed 2026-08-13](/filings/0000943819-26-000047.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:29 ET. No prices; not investment advice.